Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis
作者： Britta Galling , Amat Calsina Ferrer , Margarita Abi Zeid Daou , Dinesh Sangroula , Katsuhiko Hagi
DOI: 10.1517/14740338.2015.1085970
关键词:
摘要: Introduction: Although antidepressant (AD) monotherapy is recommended first-line for major depressive disorder (MDD), AD + co-treatment common.Areas covered: We conducted the first systematic review searching PubMed/MEDLINE/PsycInfo/Embase from database inception until 1 June 2015 acute randomized trials in ≥ 20 adults with MDD comparing that reported quantitative data on adverse events (AEs). Meta-analyzing 23 studies (n = 2435, duration 6.6 weeks) and were similar regarding intolerability-related discontinuation (risk ratio [RR] 1.38, 95% CI 0.89 – 1.10) frequency of AE (RR 1.19, 0.95 1.49). Nevertheless, was associated significantly greater burden 4/25 AEs (tremor: RR 1.55, 1.01 2.38; sweating: 1.95, 1.13 –3.38, 7% weight gain: 3.15, 1.34 7.41; gain 2.17, 0.71 3.63 kg), but not more CNS, gas...
sci-hub.se 参考文章(60)
Martin Härter, Christian Klesse, Isaac Bermejo, Frank Schneider, Mathias Berger, None, Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Deutsches Arzteblatt International. ,vol. 107, pp. 700- 708 ,(2010) , 10.3238/ARZTEBL.2010.0700
Chiara Fabbri, Stefano Porcelli, Alessandro Serretti, From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. The Canadian Journal of Psychiatry. ,vol. 59, pp. 62- 75 ,(2014) , 10.1177/070674371405900202
Atsuo Nakagawa, Norio Watanabe, Ichiro M Omori, Corrado Barbui, Andrea Cipriani, Hugh McGuire, Rachel Churchill, Toshi A Furukawa, Milnacipran versus other antidepressive agents for depression Cochrane Database of Systematic Reviews. pp. 1- 10 ,(2009) , 10.1002/14651858.CD006529.PUB2
Cengiz Akkaya, Selcuk Kırlı, Salih Saygin Eker, Sengul Cangur, Mustafa Canbazoglu, Asli Sarandol, Comparison of the efficacy and safety of sertraline, reboxetine, and venlafaxine in patients with major depressive disorder: A pooled analysis of four randomized, open-label trials Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology. ,vol. 20, pp. 274- 287 ,(2010) , 10.1080/10177833.2010.11790673
Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study American Journal of Psychiatry. ,vol. 151, pp. 1372- 1374 ,(1994) , 10.1176/AJP.151.9.1372
Jacqueline J. Martindale, Ernest H. Bennie, John M. Mullin, A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression The Journal of Clinical Psychiatry. ,vol. 56, pp. 229- 237 ,(1995)
Rasmus Licht, Susanne Qvitzau, Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology. ,vol. 161, pp. 143- 151 ,(2002) , 10.1007/S00213-002-0999-0
Michael E Thase, Edward Kim, Yonghua Jing, Rebecca Williamson, Andrei S Pikalov, Quynh-Van Tran, Rachael Fleurence, A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacology Bulletin. ,vol. 42, pp. 57- 90 ,(2009)
Britta Galling, Maryam A Garcia, Uzoma Osuchukwu, Katsuhiko Hagi, Christoph U Correll, Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis Expert Opinion on Drug Safety. ,vol. 14, pp. 1181- 1199 ,(2015) , 10.1517/14740338.2015.1053457
JEAN TIGNOL, A double-blind, randomized, fluoxetine-controlled multicenter study of paroxetine in the treatment of depression Journal of Clinical Psychopharmacology. ,vol. 13, ,(1993) , 10.1097/00004714-199312002-00003